House dust mite allergy vaccine injection - Alk-Abello
Alternative Names: Alutard; Alutard Der p; Alutard SQ; House dust mite SCIT - ALk-Abello; TO-204Latest Information Update: 26 Jun 2024
At a glance
- Originator ALK-Abello
- Developer ALK-Abello; Eddingpharm; Torii Pharmaceutical
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Asthma
Most Recent Events
- 24 Jun 2024 ALK-Abello decided to withdraw the Biologic License Application (BLA) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China.
- 24 Apr 2014 House dust mite allergy injection licensed to Eddingpharm China
- 23 Dec 2013 Preregistration for Asthma and Allergic rhinitis in Japan (SC)